Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors

NCT03983954 is registered in ClinicalTrials.gov with NeoTX Therapeutics Ltd. as lead sponsor.

NCT NCT03983954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03983954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors
Lead sponsor
NeoTX Therapeutics Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 10, 2019
Completion date
March 1, 2027
Enrollment
120 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cervical squamous cell carcinoma, colorectal cancer metastatic, endometrial cancer, er+ breast cancer, esophageal cancer, gastroesophageal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, her2-negative breast cancer, melanoma, mesothelioma, nscl2 gene mutation, nsclc, ovarian cancer, pancreatic adenocarcinoma, prostate cancer, renal cell carcinoma, triple negative breast cancer, urothelial cancer